---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013083"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:34:51.389397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026

## Summary
- Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.
- Significant tumor volume reduction across multiple PDAC models (p<0.001).
- Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).
- Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.
- No cardiotoxicity observed; supports Annamycin's differentiated safety profile.

## SEC filing metadata
- accession: 0001437749-26-013083
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/0001437749-26-013083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/mbrx20260422_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013083
- JSON: https://secwatch.observer/filing/0001437749-26-013083.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.